Corrigendum to ‘Efficacy and safety of serelaxin when added to standard of care in patients with acute heart failure: results from a PROBE study, RELAX-AHF-EU’ (European Journal of Heart Failure, (2019), 21, 3, (322-333), 10.1002/ejhf.1368);Efficacy and safety of serelaxin when added to standard of care in patients with acute heart failure: results from a PROBE study, RELAX-AHF-EU

European Journal of Heart Failure

Volumn 21, Issue 3, 2019, Pages 322-333

  Maggioni, Aldo P ^a   López Sendón, José ^b   Nielsen, Olav W ^c   Hallén, Jonas ^d   Aalamian Mattheis, Maryam ^d   Wang, Yaqin ^d   Ertl, Georg ^e  

^a ANMCO RESEARCH CENTER   (Italy)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^c BISPEBJERG HOSPITAL   (Denmark)

^d NOVARTIS PHARMA AG   (Switzerland)

^e UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Acute heart failure; Death; Europe; PROBE; Rehospitalisation; Serelaxin; Worsening heart failure

Indexed keywords

HEMOGLOBIN; SERELAXIN; CARDIOVASCULAR AGENT; RECOMBINANT PROTEIN; RELAXIN; SERELAXIN PROTEIN, HUMAN;

ACUTE HEART FAILURE; AGED; ALL CAUSE MORTALITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EUROPE; FEMALE; HEALTH CARE QUALITY; HEMATOCRIT; HOSPITAL READMISSION; HUMAN; HYPOTENSION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NUMBERS NEEDED TO TREAT; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SIDE EFFECT; ACUTE DISEASE; CAUSE OF DEATH; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG MONITORING; HEART FAILURE; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; PROCEDURES; RISK ASSESSMENT; TREATMENT OUTCOME;

ACUTE DISEASE; AGED; CARDIOVASCULAR AGENTS; CAUSE OF DEATH; DOUBLE-BLIND METHOD; DRUG MONITORING; EUROPE; FEMALE; HEART FAILURE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MORTALITY; RECOMBINANT PROTEINS; RELAXIN; RISK ADJUSTMENT; STANDARD OF CARE; TREATMENT OUTCOME;

EID: 85059477408     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.1639     Document Type: Erratum

References (29)

1. Cowie MR, Anker SD, Cleland JGF, Felker GM, Filippatos G, Jaarsma T, Jourdain P, Knight E, Massie B, Ponikowski P, Lopez-Sendon J. Improving care for patients with acute heart failure: before, during and after hospitalization. ESC Heart Fail 2014;1:110-145.
2. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013;128:1810-1852.
3. DeVore AD, Hammill BG, Sharma PP, Qualls LG, Mentz RJ, Waltman Johnson K, Fonarow GC, Curtis LH, Hernandez AF. In-hospital worsening heart failure and associations with mortality, readmission, and healthcare utilization. J Am Heart Assoc 2014;3:e001088.
4. Butler J, Gheorghiade M, Kelkar A, Fonarow GC, Anker S, Greene SJ, Papadimitriou L, Collins S, Ruschitzka F, Yancy CW, Teerlink JR, Adams K, Cotter G, Ponikowski P, Felker GM, Metra M, Filippatos G. In-hospital worsening heart failure. Eur J Heart Fail 2015;17:1104-1113.
5. Cotter G, Metra M, Weatherley BD, Dittrich HC, Massie BM, Ponikowski P, Bloomfield DM, O'Connor CM. Physician-determined worsening heart failure: a novel definition for early worsening heart failure in patients hospitalized for acute heart failure--association with signs and symptoms, hospitalization duration, and 60-day outcomes. Cardiology 2010;115:29-36.
6. Mentz RJ, Metra M, Cotter G, Milo O, McKendry C, Chiswell K, Davison BA, Cleland JG, Bloomfield DM, Dittrich HC, Fiuzat M, Ponikowski P, Givertz MM, Voors AA, Teerlink JR, O'Connor CM. Early vs. late worsening heart failure during acute heart failure hospitalization: insights from the PROTECT trial. Eur J Heart Fail 2015;17:697-706.
7. Cooper LB, Hammill BG, Sharma PP, DeVore AD, Mentz RJ, Fonarow GC, Pang PS, Curtis LH, Hernandez AF. Differences in health care use and outcomes by the timing of in-hospital worsening heart failure. Am Heart J 2015;170:1124-1132.
8. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016;18:891-975.
9. Maggioni AP, Dahlstrom U, Filippatos G, Chioncel O, Crespo Leiro M, Drozdz J, Fruhwald F, Gullestad L, Logeart D, Fabbri G, Urso R, Metra M, Parissis J, Persson H, Ponikowski P, Rauchhaus M, Voors AA, Nielsen OW, Zannad F, Tavazzi L; Heart Failure Association of the European Society of Cardiology (HFA). EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail 2013;15:808-817.
10. Curtis LH, Greiner MA, Hammill BG, Kramer JM, Whellan DJ, Schulman KA, Hernandez AF. Early and long-term outcomes of heart failure in elderly persons, 2001-2005. Arch Intern Med 2008;168:2481-2488.
11. Tavazzi L, Maggioni AP, Lucci D, Cacciatore G, Ansalone G, Oliva F, Porcu M; Italian Survey on Acute Heart Failure Investigators. Nationwide survey on acute heart failure in cardiology ward services in Italy. Eur Heart J 2006;27:1207-1215.
12. Dschietzig T, Teichman S, Unemori E, Wood S, Boehmer J, Richter C, Baumann G, Stangl K. Intravenous recombinant human relaxin in compensated heart failure: a safety, tolerability, and pharmacodynamic trial. J Card Fail 2009;15:182-190.
13. Teichman SL, Unemori E, Teerlink JR, Cotter G, Metra M. Relaxin: review of biology and potential role in treating heart failure. Curr Heart Fail Rep 2010;7:75-82.
14. Du XJ, Bathgate RA, Samuel CS, Dart AM, Summers RJ. Cardiovascular effects of relaxin: from basic science to clinical therapy. Nat Rev Cardiol 2010;7:48-58.
15. Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Ponikowski P, Unemori E, Voors AA, Adams KF, Jr., Dorobantu MI, Grinfeld LR, Jondeau G, Marmor A, Masip J, Pang PS, Werdan K, Teichman SL, Trapani A, Bush CA, Saini R, Schumacher C, Severin TM, Metra M; RELAXin in Acute Heart Failure (RELAX-AHF) Investigators. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 2013;381:29-39.
16. Metra M, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Ponikowski P, Unemori E, Voors AA, Adams KF, Jr., Dorobantu MI, Grinfeld L, Jondeau G, Marmor A, Masip J, Pang PS, Werdan K, Prescott MF, Edwards C, Teichman SL, Trapani A, Bush CA, Saini R, Schumacher C, Severin T, Teerlink JR; RELAX-AHF Investigators. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. J Am Coll Cardiol 2013;61:196-206.
17. Teerlink JR, Voors AA, Ponikowski P, Pang PS, Greenberg BH, Filippatos G, Felker GM, Davison BA, Cotter G, Gimpelewicz C, Boer-Martins L, Wernsing M, Hua TA, Severin T, Metra M. Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study. Eur J Heart Fail 2017;19:800-809.
18. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F; Chronic Kidney Disease Epidemiology Collaboration. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006;145:247-254.
19. Teerlink JR, Metra M, Felker GM, Ponikowski P, Voors AA, Weatherley BD, Marmor A, Katz A, Grzybowski J, Unemori E, Teichman SL, Cotter G. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet 2009;373:1429-1439.
20. Juni P, Altman DG, Egger M. Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ 2001;323:42-46.
21. Allen LA, Hernandez AF, O'Connor CM, Felker GM. End points for clinical trials in acute heart failure syndromes. J Am Coll Cardiol 2009;53:2248-2258.
22. Felker GM, Pang PS, Adams KF, Cleland JG, Cotter G, Dickstein K, Filippatos GS, Fonarow GC, Greenberg BH, Hernandez AF, Khan S, Komajda M, Konstam MA, Liu PP, Maggioni AP, Massie BM, McMurray JJ, Mehra M, Metra M, O'Connell J, O'Connor CM, Pina IL, Ponikowski P, Sabbah HN, Teerlink JR, Udelson JE, Yancy CW, Zannad F, Gheorghiade M; International AHFS Working Group. Clinical trials of pharmacological therapies in acute heart failure syndromes: lessons learned and directions forward. Circ Heart Fail 2010;3:314-325.
23. Felker GM, Maisel AS. A global rank end point for clinical trials in acute heart failure. Circ Heart Fail 2010;3:643-646.
24. Zannad F, Garcia AA, Anker SD, Armstrong PW, Calvo G, Cleland JG, Cohn JN, Dickstein K, Domanski MJ, Ekman I, Filippatos GS, Gheorghiade M, Hernandez AF, Jaarsma T, Koglin J, Konstam M, Kupfer S, Maggioni AP, Mebazaa A, Metra M, Nowack C, Pieske B, Pina IL, Pocock SJ, Ponikowski P, Rosano G, Ruilope LM, Ruschitzka F, Severin T, Solomon S, Stein K, Stockbridge NL, Stough WG, Swedberg K, Tavazzi L, Voors AA, Wasserman SM, Woehrle H, Zalewski A, McMurray JJ. Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. Eur J Heart Fail 2013;15:1082-1094.
25. Ziaeian B, Fonarow GC. Heart failure: heart failure clinical trials: how do we define success? Nat Rev Cardiol 2013;10:492-494.
26. Torre-Amione G, Milo-Cotter O, Kaluski E, Perchenet L, Kobrin I, Frey A, Rund MM, Weatherley BD, Cotter G. Early worsening heart failure in patients admitted for acute heart failure: time course, hemodynamic predictors, and outcome. J Card Fail 2009;15:639-644.
27. Davison BA, Metra M, Cotter G, Massie BM, Cleland JG, Dittrich HC, Edwards C, Filippatos G, Givertz MM, Greenberg B, Ponikowski P, Voors AA, O'Connor CM, Teerlink JR; PROTECT and RELAX-AHF Committees. Worsening heart failure following admission for acute heart failure: a pooled analysis of the PROTECT and RELAX-AHF studies. JACC Heart Fail 2015;3:395-403.
28. Cooper LB, DeVore AD, Michael Felker G. The impact of worsening heart failure in the United States. Heart Fail Clin 2015;11:603-614.
29. Fonseca C, Maggioni AP, Marques F, Araujo I, Bras D, Langdon RB, Lombardi C, Bettencourt P. A systematic review of in-hospital worsening heart failure as an endpoint in clinical investigations of therapy for acute heart failure. Int J Cardiol 2018;250:215-222.